GLENMARK5 hours ago
Glenmark Pharmaceuticals Limited (glenmark) Announces IND Submission for ISB 2301
Glenmark Pharmaceuticals Limited (GLENMARK) announces IND submission for ISB 2301, a first-in-class multispecific immune cell activator targeting solid tumors.